Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria

Rabin Medical Center20 enrolled

Overview

The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or oral corticosteroids.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Idiopathic Urticaria

Interventions

OmalizimabDRUG

Omalizimab 150 mg S.C. once a month for consecutive 3 months

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diagnosis of chronic idiopathic urticaria for 3 months * failure on treatment with at least 2 antihistamins and systemic corticosteroids or cyclosporin Exclusion Criteria: * physical or cholinergic urticaria * past treatment in Omalizumab i nprevious year * parasitic infection * malignancy in last 5 years * known sensitivity to Omalizumab

Locations (1)

Rabin Medical Center

Petah Tikva, Israel, Israel

Outcomes

Primary Outcomes

Percentage of Participants with ≥ 50% Decrease in Urticaria Activity Score (UAS)

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.